US 12,104,213 B2
Compositions, kits and methods for detection of campylobacter nucleic acid
Michael R. Reshatoff, Jr., San Diego, CA (US); Jennifer J. Bungo, San Diego, CA (US); Shannon K. Kaplan, San Diego, CA (US); and James J. Hogan, Coronado, CA (US)
Assigned to GEN-PROBE INCORPORATED, San Diego, CA (US)
Filed by GEN-PROBE INCORPORATED, San Diego, CA (US)
Filed on Jul. 20, 2020, as Appl. No. 16/933,341.
Application 14/927,785 is a division of application No. 13/128,384, granted, now 9,175,353, issued on Nov. 3, 2015, previously published as PCT/US2009/064516, filed on Nov. 16, 2009.
Application 16/933,341 is a continuation of application No. 14/927,785, filed on Oct. 30, 2015, granted, now 10,829,824.
Claims priority of provisional application 61/114,547, filed on Nov. 14, 2008.
Prior Publication US 2020/0354775 A1, Nov. 12, 2020
Int. Cl. C12Q 1/68 (2018.01); C12Q 1/689 (2018.01)
CPC C12Q 1/689 (2013.01) [C12Q 2600/158 (2013.01); Y02A 50/30 (2018.01)] 19 Claims
 
1. A method for specifically detecting one or more of a Campylobacter jejuni, a Campylobacter coli, and a Campylobacter lari target nucleic acid in a sample comprising the steps of:
(a) obtaining a sample suspected of containing at least one of the Campylobacter jejuni, a Campylobacter coli, and a Campylobacter lari target nucleic acid;
(b) contacting said sample with a buffer, an inorganic salt, dNTPs, and a combination of a first amplification oligomer and a second amplification oligomer, wherein the first amplification oligomer is 15-70 nucleotides in length and comprises a contiguous target hybridizing sequence 15 to 45 nucleotides in length configured to hybridize to a sequence in a region of a Campylobacter 16S rRNA gene corresponding to nucleotides 83 to 150 of SEQ ID NO:91, wherein the second amplification oligomer is 15-70 nucleotides in length and comprises a contiguous target hybridizing sequence 15 to 45 nucleotides in length configured to hybridize to a sequence in a region of the Campylobacter 16S rRNA gene corresponding to nucleotides 170 to 226 of SEQ ID NO:91, and wherein the first amplification oligomer and the second amplification oligomer comprises target hybridizing sequences selected from the group consisting of:
(i) SEQ ID NO:19 and SEQ ID NO:4;
(ii) SEQ ID NO:19 and SEQ ID NO:7;
(iii) SEQ ID NO:19 and SEQ ID NO:12;
(iv) SEQ ID NO:33 and SEQ ID NO:7;
(v) SEQ ID NO:33 and SEQ ID NO:12;
(vi) SEQ ID NO:49 and SEQ ID NO:4;
(vii) SEQ ID NO:49 and SEQ ID NO:7;
(viii) SEQ ID NO:49 and SEQ ID NO:12;
(ix) SEQ ID NO:29 and SEQ ID NO:7;
(x) SEQ ID NO:31 and SEQ ID NO:7;
(xi) SEQ ID NO:25 and SEQ ID NO:7;
(xii) SEQ ID NO:25 and SEQ ID NO:12;
(xiii) SEQ ID NO:33 and SEQ ID NO:4; and
(xiv) SEQ ID NO:33 and SEQ ID NO:7;
(c) performing an in vitro nucleic acid amplification reaction wherein any of the one or more of the Campylobacter jejuni, the Campylobacter coli, and the Campylobacter lari target nucleic acid, if present in the sample, is used as a template for generating an amplification product; and
(d) performing a nucleic acid detection reaction that detects the amplification product, wherein detection of the amplification product indicates presence of Campylobacter jejuni, Campylobacter coli, and/or Campylobacter lari in the sample and absence of detection of the amplification product indicates absence of Campylobacter jejuni, Campylobacter coli, and Campylobacter lari in the sample.